Myeloproliferative disease

This page contains recent news articles, when available, and an overview of Myeloproliferative disease but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Myeloproliferative disease

Novel Tumor Suppressor Discovered  -  ‎Aug 3, 2009‎
Science Daily (press release)He and his team set out to investigate further, choosing to focus specifically on myeloproliferative disease because almost all of the mice with a defective

Incyte Corporation Q2 2009 Earnings Call Transcript  -  ‎Jul 30, 2009‎
Seeking Alpha...a strong rest of the world partner could help us rapidly optimize the myeloproliferative disease opportunity as well as improve our financial position.

Incyte Reports Progress in Multiple Clinical Programs Announces ...  -  Nov 6, 2008
Genetic Engineering News (press release),Janus Kinase (JAK) Inhibitor Program ------------------------------------- INCB18424: Myelofibrosis (MF), a life-threatening myeloproliferative disease

Modélisation de la dynamique de l’hématopoïèse normale et pathologique  -  Nov 12, 2008
Hématologie,Myeloproliferative Disorders Hydroxyurea and periodicity in myeloproliferative disease. Eur J Haematol 2001 ; 66 : 317-23. 24 Morley A, Baikie A,

After transplant, a quiet recovery  -  Jul 3, 2008
Philadelphia Inquirer,Ever the competitor, Bucci was eager to deal with his cancer, a condition known as chronic myeloproliferative disease, as swiftly as possible.

Singapore drug-development firm receives 'orphan' approval from US  -  May 14, 2008
Earthtimes (press release),Singapore - The drug-development firm S*Bio has been granted "orphan" approval from the US Food and Drug Administration (FDA) for a product aimed a treating

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative ...  -  Mar 17, 2008
Earthtimes,This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease.

Upbeat outlook on life  -  Feb 29, 2008
Journal Times,When Blocks started the Myeloproliferative Disease Support Group, she thought it might just be her and another woman — the only other person she’d found in

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 ...  -  Dec 6, 2007
ReutersTargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH SAN

Rockefeller Cancer Center Work Coming  -  Dec 4, 2007
Houston Chronicle,...who died in July 2006 after unsuccessful treatment in Seattle for myeloproliferative disease, a blood disorder that can lead to leukemia.

Three Astex Drug Candidates to be Presented at the 2007 American ...  -  Nov 28, 2007
PR Newswire (press release),Is Active in JAK2 V617F Myeloproliferative Disease Models. Session Name: Myeloproliferative Syndromes: Therapy Session Date: Monday, December 10,

Portal vein thrombosis is common in extraportal vein obstruction  -  Oct 12, 2007
HULIQ,The role of JAK2mutation in the early diagnosis of overt or silent myeloproliferative disease cannot be undermined but requires standardization.

Arkansas News Bureau  -  Sep 29, 2007
Arkansas News,...bone marrow transplants at a Seattle cancer center in an attempt to treat his myeloproliferative disease, a blood disorder related to leukemia.

Ark. Cancer Center renamed for Win Rockefeller  -  Sep 28, 2007
Pine Bluff Commercial,Rockefeller died in July 2006 after unsuccessful treatment in Seattle for myeloproliferative disease, a blood disorder that can lead to leukemia. He was 57.



Background information on Myeloproliferative disease [When available]

The myeloproliferative diseases are a group of diseases of the bone marrow where excess cells are produced. The delineation from leukemia is artificial, although the myeloproliferative diseases on the whole have a much better prognosis than the leukemias. The concept was first proposed in 1951 by the eminent hematologist William Dameshek.

The myeloproliferative diseases are:
  • Chronic myelogenous leukemia (CML)
  • Polycythemia vera (PCV)
  • Essential thrombocytosis (ET)
  • Myelofibrosis (increased connective tissue with decreased room for production of normal blood cells).
All MPDs arise from precursors of the "myeloid" lineage in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).

Search the web for more resources on Myeloproliferative disease



Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy